New psoriasis drug shows promise in Mid-Stage trial
NCT ID NCT06592274
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial is testing a new biologic drug called HB0017 in 200 adults with moderate to severe plaque psoriasis. Participants receive different doses and schedules of the injection to see how well it clears skin plaques and how safe it is. The study is double-blind and randomized, meaning neither patients nor doctors know who gets which dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HB0017 injection (a biologic drug)
- What this could lead to
- If successful, this could lead to a new treatment option that helps clear psoriasis plaques with less frequent injections.
- What could go wrong
- This is an early Phase 2 trial with only 200 people, so results may not apply to everyone. The drug may not work better than existing treatments or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS (PSO) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chongqing Traditional Chinese Medicine Hospital
RECRUITINGChongqing, Sichuan, China
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, China
-
Hangzhou First People's Hospital
RECRUITINGHangzhou, Zhejiang, China
-
Jiangsu University Affiliated Hospital
RECRUITINGZhenjiang, Jiangsu, China
-
Jiaxing First Hospital
RECRUITINGJiaxing, Zhejiang, China
-
Jilin University Second Hospital
RECRUITINGChangchun, Jilin, China
-
Jining First People's Hospital
RECRUITINGJining, Shandong, 0531, China
-
Ningbo Second Hospital
RECRUITINGNingbo, China
-
Shandong First Medical University Affiliated Dermatology Hospital
NOT_YET_RECRUITINGJinan, Shandong, 0531, China
-
Shanxi Medical University Second Hospital
RECRUITINGTaiyuan, Shanxi, China
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, China
-
Southern Medical University Dermatology Hospital
RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital of Bengbu Medical College
RECRUITINGBengbu, Anhui, China
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
-
Wenzhou Medical University Affiliated First Hospital
RECRUITINGWenzhou, Zhejiang, China
-
Wuxi Second People's Hospital
RECRUITINGWuxi, Jiangsu, China
-
Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, China
-
Xingtai People's Hospital
RECRUITINGXingtai, Shandong, 0531, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common blood thinner shield psoriasis Patients' arteries?
- Can a new pill tame psoriasis? early safety trial begins
- Psoriasis patients: does your injection schedule matter?
- New psoriasis cream takes on old standby in Head-to-Head trial
- World's largest psoriasis care study launches to uncover treatment gaps
- Fasting diet shows promise for psoriasis relief